Page last updated: 2024-09-02

ecteinascidin 743 and Retroperitoneal Neoplasms

ecteinascidin 743 has been researched along with Retroperitoneal Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Decoupigny, E; Isambert, N; Le Cesne, A; Penel, N; Taieb, S; Tresch-Bruneel, E1
Almond, M; Beggs, A; Desai, A; Ford, S; Taniere, P; Tyler, R; Wanigasooriya, K1
Amano, K; Chika, N; Fukuchi, M; Hatano, S; Ishibashi, K; Ishida, H; Ishiguro, T; Ito, T; Kumagai, Y; Mochiki, E; Muramatsu, S; Muta, Y; Suzuki, O; Toyomasu, Y1
Badalamenti, G; Bello, E; Casali, PG; Collini, P; Colombo, C; Cominetti, D; D'Incalci, M; Dagrada, GP; Dei Tos, AP; Frapolli, R; Gronchi, A; Morosi, C; Negri, T; Pilotti, S; Provenzano, S; Renne, SL; Saponara, M; Stacchiotti, S; Tortoreto, M; Vincenzi, B; Zaffaroni, N; Zuco, V1

Reviews

1 review(s) available for ecteinascidin 743 and Retroperitoneal Neoplasms

ArticleYear
A review of retroperitoneal liposarcoma genomics.
    Cancer treatment reviews, 2020, Volume: 86

    Topics: Animals; Antineoplastic Agents, Alkylating; Chromosome Aberrations; Genomics; Humans; Liposarcoma; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Retroperitoneal Neoplasms; Trabectedin

2020

Other Studies

3 other study(ies) available for ecteinascidin 743 and Retroperitoneal Neoplasms

ArticleYear
Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient With Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum From the T-Dis Trial.
    American journal of clinical oncology, 2019, Volume: 42, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Female; Histiocytoma, Malignant Fibrous; Humans; Mediastinal Neoplasms; Middle Aged; Prognosis; Retroperitoneal Neoplasms; Sarcoma; Trabectedin

2019
[A Case of Giant Retroperitoneal Liposarcoma Resected after Trabectedin Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13

    Topics: Antineoplastic Agents, Alkylating; Humans; Liposarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Retroperitoneal Neoplasms; Trabectedin

2018
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 76

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar Neoplasms; Dacarbazine; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Furans; Humans; Ifosfamide; Ketones; Kidney Neoplasms; Male; Meningeal Neoplasms; Mice, SCID; Middle Aged; Pleural Neoplasms; Response Evaluation Criteria in Solid Tumors; Retroperitoneal Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Solitary Fibrous Tumors; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays

2017